nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—prostate cancer—Hydrocortisone—psoriasis	0.224	0.388	CpDpCtD
Metoclopramide—CYP11B2—Hydrocortisone—psoriasis	0.14	0.43	CbGbCtD
Metoclopramide—prostate cancer—Dexamethasone—psoriasis	0.137	0.237	CpDpCtD
Metoclopramide—prostate cancer—Betamethasone—psoriasis	0.137	0.237	CpDpCtD
Metoclopramide—CYP11B1—Hydrocortisone—psoriasis	0.0912	0.279	CbGbCtD
Metoclopramide—migraine—Prednisone—psoriasis	0.0796	0.138	CpDpCtD
Metoclopramide—CYP17A1—Dexamethasone—psoriasis	0.0567	0.174	CbGbCtD
Metoclopramide—CYP2D6—Hydroxyurea—psoriasis	0.0168	0.0514	CbGbCtD
Metoclopramide—CYP2D6—Cholecalciferol—psoriasis	0.0102	0.0312	CbGbCtD
Metoclopramide—CYP2D6—Cyclosporine—psoriasis	0.00668	0.0205	CbGbCtD
Metoclopramide—CYP2D6—Dexamethasone—psoriasis	0.0044	0.0135	CbGbCtD
Metoclopramide—CYP11B2—ACE Inhibitor Pathway—REN—psoriasis	0.00163	0.0687	CbGpPWpGaD
Metoclopramide—CYP11B2—ACE Inhibitor Pathway—ACE—psoriasis	0.00101	0.0429	CbGpPWpGaD
Metoclopramide—Sunitinib—TYK2—psoriasis	0.00099	1	CrCbGaD
Metoclopramide—CYP11B2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000985	0.0416	CbGpPWpGaD
Metoclopramide—CYP11B2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000972	0.0411	CbGpPWpGaD
Metoclopramide—CYP11B1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000848	0.0359	CbGpPWpGaD
Metoclopramide—CYP11B1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000837	0.0354	CbGpPWpGaD
Metoclopramide—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000834	0.0353	CbGpPWpGaD
Metoclopramide—CYP11B2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000798	0.0338	CbGpPWpGaD
Metoclopramide—CYP17A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000794	0.0336	CbGpPWpGaD
Metoclopramide—CYP17A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000783	0.0331	CbGpPWpGaD
Metoclopramide—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000778	0.0329	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—IVL—psoriasis	0.000709	0.03	CbGpPWpGaD
Metoclopramide—CYP11B1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000688	0.0291	CbGpPWpGaD
Metoclopramide—CYP17A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000643	0.0272	CbGpPWpGaD
Metoclopramide—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000517	0.0219	CbGpPWpGaD
Metoclopramide—CYP11B2—Biological oxidations—CYP2S1—psoriasis	0.000424	0.0179	CbGpPWpGaD
Metoclopramide—CYP11B2—Metapathway biotransformation—CYP2S1—psoriasis	0.000418	0.0177	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000388	0.0164	CbGpPWpGaD
Metoclopramide—CYP11B1—Biological oxidations—CYP2S1—psoriasis	0.000365	0.0154	CbGpPWpGaD
Metoclopramide—CYP11B1—Metapathway biotransformation—CYP2S1—psoriasis	0.00036	0.0152	CbGpPWpGaD
Metoclopramide—CYP17A1—Biological oxidations—CYP2S1—psoriasis	0.000342	0.0145	CbGpPWpGaD
Metoclopramide—CYP17A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000337	0.0143	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—HCAR2—psoriasis	0.000296	0.0125	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000258	0.0109	CbGpPWpGaD
Metoclopramide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000215	0.00908	CbGpPWpGaD
Metoclopramide—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000212	0.00896	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—IL13—psoriasis	0.000203	0.0086	CbGpPWpGaD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000202	0.00853	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—HCAR2—psoriasis	0.000178	0.00754	CbGpPWpGaD
Metoclopramide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000174	0.00736	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—HCAR2—psoriasis	0.000167	0.00707	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—CCL20—psoriasis	0.000154	0.0065	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HCAR2—psoriasis	0.000152	0.00642	CbGpPWpGaD
Metoclopramide—CHRM1—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000146	0.00616	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000142	0.006	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—HCAR2—psoriasis	0.000136	0.00577	CbGpPWpGaD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—NFKBIA—psoriasis	0.000131	0.00554	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—IL10—psoriasis	0.000127	0.00538	CbGpPWpGaD
Metoclopramide—Diarrhoea—Acitretin—psoriasis	0.000124	0.00173	CcSEcCtD
Metoclopramide—Anxiety—Mycophenolic acid—psoriasis	0.000124	0.00173	CcSEcCtD
Metoclopramide—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000123	0.00173	CcSEcCtD
Metoclopramide—Cardiac arrest—Prednisone—psoriasis	0.000123	0.00172	CcSEcCtD
Metoclopramide—Bradycardia—Hydrocortisone—psoriasis	0.000122	0.00171	CcSEcCtD
Metoclopramide—Fatigue—Hydroxyurea—psoriasis	0.000122	0.00171	CcSEcCtD
Metoclopramide—Nausea—Calcitriol—psoriasis	0.000121	0.00169	CcSEcCtD
Metoclopramide—Confusional state—Mycophenolic acid—psoriasis	0.00012	0.00168	CcSEcCtD
Metoclopramide—Hallucination—Hydrocortisone—psoriasis	0.00012	0.00167	CcSEcCtD
Metoclopramide—Dizziness—Acitretin—psoriasis	0.00012	0.00167	CcSEcCtD
Metoclopramide—Dizziness—Fluocinolone Acetonide—psoriasis	0.000119	0.00167	CcSEcCtD
Metoclopramide—Oedema—Mycophenolic acid—psoriasis	0.000119	0.00166	CcSEcCtD
Metoclopramide—Visual impairment—Prednisolone—psoriasis	0.000119	0.00166	CcSEcCtD
Metoclopramide—Feeling abnormal—Hydroxyurea—psoriasis	0.000117	0.00164	CcSEcCtD
Metoclopramide—Tachycardia—Mycophenolic acid—psoriasis	0.000116	0.00162	CcSEcCtD
Metoclopramide—Bradycardia—Triamcinolone—psoriasis	0.000115	0.00161	CcSEcCtD
Metoclopramide—Nervousness—Cyclosporine—psoriasis	0.000114	0.0016	CcSEcCtD
Metoclopramide—Visual disturbance—Methotrexate—psoriasis	0.000114	0.0016	CcSEcCtD
Metoclopramide—Rash—Acitretin—psoriasis	0.000114	0.00159	CcSEcCtD
Metoclopramide—Dermatitis—Acitretin—psoriasis	0.000114	0.00159	CcSEcCtD
Metoclopramide—Rash—Fluocinolone Acetonide—psoriasis	0.000114	0.00159	CcSEcCtD
Metoclopramide—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000114	0.00159	CcSEcCtD
Metoclopramide—Muscle spasms—Cyclosporine—psoriasis	0.000113	0.00158	CcSEcCtD
Metoclopramide—Headache—Acitretin—psoriasis	0.000113	0.00158	CcSEcCtD
Metoclopramide—Headache—Fluocinolone Acetonide—psoriasis	0.000113	0.00158	CcSEcCtD
Metoclopramide—Body temperature increased—Hydroxyurea—psoriasis	0.000112	0.00157	CcSEcCtD
Metoclopramide—Nervousness—Mycophenolate mofetil—psoriasis	0.000112	0.00156	CcSEcCtD
Metoclopramide—Hypotension—Mycophenolic acid—psoriasis	0.000111	0.00155	CcSEcCtD
Metoclopramide—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000111	0.00155	CcSEcCtD
Metoclopramide—Tremor—Cyclosporine—psoriasis	0.00011	0.00154	CcSEcCtD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000109	0.00459	CbGpPWpGaD
Metoclopramide—Agitation—Cyclosporine—psoriasis	0.000108	0.00151	CcSEcCtD
Metoclopramide—DRD3—GPCR ligand binding—HCAR2—psoriasis	0.000108	0.00457	CbGpPWpGaD
Metoclopramide—Tremor—Mycophenolate mofetil—psoriasis	0.000108	0.00151	CcSEcCtD
Metoclopramide—Angioedema—Cyclosporine—psoriasis	0.000108	0.00151	CcSEcCtD
Metoclopramide—Insomnia—Mycophenolic acid—psoriasis	0.000108	0.0015	CcSEcCtD
Metoclopramide—Nausea—Acitretin—psoriasis	0.000107	0.0015	CcSEcCtD
Metoclopramide—Nausea—Fluocinolone Acetonide—psoriasis	0.000107	0.0015	CcSEcCtD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000106	0.00449	CbGpPWpGaD
Metoclopramide—Dyspnoea—Mycophenolic acid—psoriasis	0.000106	0.00148	CcSEcCtD
Metoclopramide—Somnolence—Mycophenolic acid—psoriasis	0.000106	0.00148	CcSEcCtD
Metoclopramide—Agitation—Mycophenolate mofetil—psoriasis	0.000106	0.00148	CcSEcCtD
Metoclopramide—Leukopenia—Cyclosporine—psoriasis	0.000105	0.00148	CcSEcCtD
Metoclopramide—Angioedema—Mycophenolate mofetil—psoriasis	0.000105	0.00147	CcSEcCtD
Metoclopramide—Bradycardia—Dexamethasone—psoriasis	0.000105	0.00146	CcSEcCtD
Metoclopramide—Bradycardia—Betamethasone—psoriasis	0.000105	0.00146	CcSEcCtD
Metoclopramide—Hypersensitivity—Hydroxyurea—psoriasis	0.000105	0.00146	CcSEcCtD
Metoclopramide—Neutropenia—Prednisone—psoriasis	0.000105	0.00146	CcSEcCtD
Metoclopramide—Erectile dysfunction—Prednisone—psoriasis	0.000103	0.00144	CcSEcCtD
Metoclopramide—Leukopenia—Mycophenolate mofetil—psoriasis	0.000103	0.00144	CcSEcCtD
Metoclopramide—Fatigue—Mycophenolic acid—psoriasis	0.000102	0.00143	CcSEcCtD
Metoclopramide—Hallucination—Betamethasone—psoriasis	0.000102	0.00143	CcSEcCtD
Metoclopramide—Hallucination—Dexamethasone—psoriasis	0.000102	0.00143	CcSEcCtD
Metoclopramide—Convulsion—Cyclosporine—psoriasis	0.000102	0.00143	CcSEcCtD
Metoclopramide—Asthenia—Hydroxyurea—psoriasis	0.000102	0.00142	CcSEcCtD
Metoclopramide—Hypertension—Cyclosporine—psoriasis	0.000102	0.00142	CcSEcCtD
Metoclopramide—Palpitations—Mycophenolate mofetil—psoriasis	0.000102	0.00142	CcSEcCtD
Metoclopramide—Anxiety—Cyclosporine—psoriasis	0.0001	0.0014	CcSEcCtD
Metoclopramide—Convulsion—Mycophenolate mofetil—psoriasis	9.96e-05	0.00139	CcSEcCtD
Metoclopramide—Depression—Prednisone—psoriasis	9.94e-05	0.00139	CcSEcCtD
Metoclopramide—Hypertension—Mycophenolate mofetil—psoriasis	9.92e-05	0.00139	CcSEcCtD
Metoclopramide—Visual impairment—Dexamethasone—psoriasis	9.9e-05	0.00139	CcSEcCtD
Metoclopramide—Visual impairment—Betamethasone—psoriasis	9.9e-05	0.00139	CcSEcCtD
Metoclopramide—Angioedema—Prednisolone—psoriasis	9.8e-05	0.00137	CcSEcCtD
Metoclopramide—Feeling abnormal—Mycophenolic acid—psoriasis	9.8e-05	0.00137	CcSEcCtD
Metoclopramide—Anxiety—Mycophenolate mofetil—psoriasis	9.75e-05	0.00136	CcSEcCtD
Metoclopramide—Diarrhoea—Hydroxyurea—psoriasis	9.71e-05	0.00136	CcSEcCtD
Metoclopramide—Confusional state—Cyclosporine—psoriasis	9.7e-05	0.00136	CcSEcCtD
Metoclopramide—Oedema—Cyclosporine—psoriasis	9.62e-05	0.00134	CcSEcCtD
Metoclopramide—Angioedema—Hydrocortisone—psoriasis	9.57e-05	0.00134	CcSEcCtD
Metoclopramide—Confusional state—Mycophenolate mofetil—psoriasis	9.46e-05	0.00132	CcSEcCtD
Metoclopramide—Body temperature increased—Mycophenolic acid—psoriasis	9.4e-05	0.00131	CcSEcCtD
Metoclopramide—Dizziness—Hydroxyurea—psoriasis	9.39e-05	0.00131	CcSEcCtD
Metoclopramide—Oedema—Mycophenolate mofetil—psoriasis	9.38e-05	0.00131	CcSEcCtD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—CXCL8—psoriasis	9.35e-05	0.00395	CbGpPWpGaD
Metoclopramide—Asthma—Methotrexate—psoriasis	9.35e-05	0.00131	CcSEcCtD
Metoclopramide—Convulsion—Prednisolone—psoriasis	9.29e-05	0.0013	CcSEcCtD
Metoclopramide—DRD3—G alpha (i) signalling events—CCL20—psoriasis	9.26e-05	0.00392	CbGpPWpGaD
Metoclopramide—Hypertension—Prednisolone—psoriasis	9.26e-05	0.00129	CcSEcCtD
Metoclopramide—CYP2D6—Biological oxidations—CYP2S1—psoriasis	9.24e-05	0.00391	CbGpPWpGaD
Metoclopramide—Tachycardia—Mycophenolate mofetil—psoriasis	9.16e-05	0.00128	CcSEcCtD
Metoclopramide—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	9.11e-05	0.00385	CbGpPWpGaD
Metoclopramide—Bradycardia—Prednisone—psoriasis	9.11e-05	0.00127	CcSEcCtD
Metoclopramide—Convulsion—Hydrocortisone—psoriasis	9.07e-05	0.00127	CcSEcCtD
Metoclopramide—Hypertension—Hydrocortisone—psoriasis	9.04e-05	0.00126	CcSEcCtD
Metoclopramide—Angioedema—Triamcinolone—psoriasis	9.01e-05	0.00126	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—HCAR2—psoriasis	8.97e-05	0.00379	CbGpPWpGaD
Metoclopramide—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	8.96e-05	0.00379	CbGpPWpGaD
Metoclopramide—Rash—Hydroxyurea—psoriasis	8.95e-05	0.00125	CcSEcCtD
Metoclopramide—Dermatitis—Hydroxyurea—psoriasis	8.94e-05	0.00125	CcSEcCtD
Metoclopramide—Hallucination—Prednisone—psoriasis	8.91e-05	0.00125	CcSEcCtD
Metoclopramide—Headache—Hydroxyurea—psoriasis	8.89e-05	0.00124	CcSEcCtD
Metoclopramide—Anxiety—Hydrocortisone—psoriasis	8.88e-05	0.00124	CcSEcCtD
Metoclopramide—Hypotension—Mycophenolate mofetil—psoriasis	8.77e-05	0.00123	CcSEcCtD
Metoclopramide—Oedema—Prednisolone—psoriasis	8.75e-05	0.00122	CcSEcCtD
Metoclopramide—Neutropenia—Methotrexate—psoriasis	8.74e-05	0.00122	CcSEcCtD
Metoclopramide—Insomnia—Cyclosporine—psoriasis	8.7e-05	0.00122	CcSEcCtD
Metoclopramide—HTR4—GPCR downstream signaling—CCL20—psoriasis	8.68e-05	0.00367	CbGpPWpGaD
Metoclopramide—Erectile dysfunction—Methotrexate—psoriasis	8.61e-05	0.0012	CcSEcCtD
Metoclopramide—Dyspnoea—Cyclosporine—psoriasis	8.57e-05	0.0012	CcSEcCtD
Metoclopramide—Somnolence—Cyclosporine—psoriasis	8.55e-05	0.0012	CcSEcCtD
Metoclopramide—Oedema—Hydrocortisone—psoriasis	8.55e-05	0.0012	CcSEcCtD
Metoclopramide—Convulsion—Triamcinolone—psoriasis	8.54e-05	0.00119	CcSEcCtD
Metoclopramide—Tachycardia—Prednisolone—psoriasis	8.54e-05	0.00119	CcSEcCtD
Metoclopramide—Asthenia—Mycophenolic acid—psoriasis	8.53e-05	0.00119	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—NDUFA5—psoriasis	8.53e-05	0.00361	CbGpPWpGaD
Metoclopramide—Hypertension—Triamcinolone—psoriasis	8.51e-05	0.00119	CcSEcCtD
Metoclopramide—Insomnia—Mycophenolate mofetil—psoriasis	8.48e-05	0.00119	CcSEcCtD
Metoclopramide—Nausea—Hydroxyurea—psoriasis	8.43e-05	0.00118	CcSEcCtD
Metoclopramide—CYP11B1—Corticotropin-releasing hormone—NFKB1—psoriasis	8.37e-05	0.00354	CbGpPWpGaD
Metoclopramide—Dyspnoea—Mycophenolate mofetil—psoriasis	8.36e-05	0.00117	CcSEcCtD
Metoclopramide—Tachycardia—Hydrocortisone—psoriasis	8.34e-05	0.00117	CcSEcCtD
Metoclopramide—Somnolence—Mycophenolate mofetil—psoriasis	8.34e-05	0.00117	CcSEcCtD
Metoclopramide—Drowsiness—Methotrexate—psoriasis	8.33e-05	0.00117	CcSEcCtD
Metoclopramide—Depression—Methotrexate—psoriasis	8.31e-05	0.00116	CcSEcCtD
Metoclopramide—Flushing—Prednisone—psoriasis	8.31e-05	0.00116	CcSEcCtD
Metoclopramide—Fatigue—Cyclosporine—psoriasis	8.29e-05	0.00116	CcSEcCtD
Metoclopramide—DRD2—GPCR ligand binding—HCAR2—psoriasis	8.26e-05	0.00349	CbGpPWpGaD
Metoclopramide—Angioedema—Betamethasone—psoriasis	8.18e-05	0.00114	CcSEcCtD
Metoclopramide—Angioedema—Dexamethasone—psoriasis	8.18e-05	0.00114	CcSEcCtD
Metoclopramide—Diarrhoea—Mycophenolic acid—psoriasis	8.13e-05	0.00114	CcSEcCtD
Metoclopramide—CHRM1—GPCR ligand binding—HCAR2—psoriasis	8.09e-05	0.00342	CbGpPWpGaD
Metoclopramide—Oedema—Triamcinolone—psoriasis	8.05e-05	0.00113	CcSEcCtD
Metoclopramide—Hypotension—Hydrocortisone—psoriasis	7.99e-05	0.00112	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.95e-05	0.00336	CbGpPWpGaD
Metoclopramide—Feeling abnormal—Cyclosporine—psoriasis	7.92e-05	0.00111	CcSEcCtD
Metoclopramide—Insomnia—Prednisolone—psoriasis	7.91e-05	0.00111	CcSEcCtD
Metoclopramide—HTR4—Signaling by GPCR—CCL20—psoriasis	7.88e-05	0.00333	CbGpPWpGaD
Metoclopramide—Dizziness—Mycophenolic acid—psoriasis	7.86e-05	0.0011	CcSEcCtD
Metoclopramide—Tachycardia—Triamcinolone—psoriasis	7.85e-05	0.0011	CcSEcCtD
Metoclopramide—Agranulocytosis—Methotrexate—psoriasis	7.78e-05	0.00109	CcSEcCtD
Metoclopramide—HTR4—Signaling Pathways—TAGAP—psoriasis	7.77e-05	0.00329	CbGpPWpGaD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—CP—psoriasis	7.76e-05	0.00328	CbGpPWpGaD
Metoclopramide—Convulsion—Dexamethasone—psoriasis	7.75e-05	0.00108	CcSEcCtD
Metoclopramide—Convulsion—Betamethasone—psoriasis	7.75e-05	0.00108	CcSEcCtD
Metoclopramide—Feeling abnormal—Mycophenolate mofetil—psoriasis	7.73e-05	0.00108	CcSEcCtD
Metoclopramide—Insomnia—Hydrocortisone—psoriasis	7.73e-05	0.00108	CcSEcCtD
Metoclopramide—Hypertension—Dexamethasone—psoriasis	7.72e-05	0.00108	CcSEcCtD
Metoclopramide—Hypertension—Betamethasone—psoriasis	7.72e-05	0.00108	CcSEcCtD
Metoclopramide—Urticaria—Cyclosporine—psoriasis	7.64e-05	0.00107	CcSEcCtD
Metoclopramide—Body temperature increased—Cyclosporine—psoriasis	7.6e-05	0.00106	CcSEcCtD
Metoclopramide—Anxiety—Dexamethasone—psoriasis	7.59e-05	0.00106	CcSEcCtD
Metoclopramide—Anxiety—Betamethasone—psoriasis	7.59e-05	0.00106	CcSEcCtD
Metoclopramide—Rash—Mycophenolic acid—psoriasis	7.49e-05	0.00105	CcSEcCtD
Metoclopramide—Dermatitis—Mycophenolic acid—psoriasis	7.49e-05	0.00105	CcSEcCtD
Metoclopramide—Urticaria—Mycophenolate mofetil—psoriasis	7.45e-05	0.00104	CcSEcCtD
Metoclopramide—Headache—Mycophenolic acid—psoriasis	7.45e-05	0.00104	CcSEcCtD
Metoclopramide—Body temperature increased—Mycophenolate mofetil—psoriasis	7.42e-05	0.00104	CcSEcCtD
Metoclopramide—HTR3A—Transmembrane transport of small molecules—CARM1—psoriasis	7.4e-05	0.00313	CbGpPWpGaD
Metoclopramide—Fatigue—Hydrocortisone—psoriasis	7.37e-05	0.00103	CcSEcCtD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.37e-05	0.00311	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—NDUFA5—psoriasis	7.35e-05	0.00311	CbGpPWpGaD
Metoclopramide—Oedema—Dexamethasone—psoriasis	7.3e-05	0.00102	CcSEcCtD
Metoclopramide—Oedema—Betamethasone—psoriasis	7.3e-05	0.00102	CcSEcCtD
Metoclopramide—Insomnia—Triamcinolone—psoriasis	7.28e-05	0.00102	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—CYP2S1—psoriasis	7.25e-05	0.00307	CbGpPWpGaD
Metoclopramide—Feeling abnormal—Prednisolone—psoriasis	7.21e-05	0.00101	CcSEcCtD
Metoclopramide—Visual impairment—Methotrexate—psoriasis	7.21e-05	0.00101	CcSEcCtD
Metoclopramide—Dyspnoea—Triamcinolone—psoriasis	7.17e-05	0.001	CcSEcCtD
Metoclopramide—Agitation—Prednisone—psoriasis	7.16e-05	0.001	CcSEcCtD
Metoclopramide—Tachycardia—Dexamethasone—psoriasis	7.13e-05	0.000997	CcSEcCtD
Metoclopramide—Tachycardia—Betamethasone—psoriasis	7.13e-05	0.000997	CcSEcCtD
Metoclopramide—Angioedema—Prednisone—psoriasis	7.12e-05	0.000996	CcSEcCtD
Metoclopramide—DRD2—G alpha (i) signalling events—CCL20—psoriasis	7.09e-05	0.003	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Cyclosporine—psoriasis	7.09e-05	0.000991	CcSEcCtD
Metoclopramide—Nausea—Mycophenolic acid—psoriasis	7.06e-05	0.000987	CcSEcCtD
Metoclopramide—Feeling abnormal—Hydrocortisone—psoriasis	7.04e-05	0.000985	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—CXCL8—psoriasis	6.96e-05	0.00294	CbGpPWpGaD
Metoclopramide—Urticaria—Prednisolone—psoriasis	6.95e-05	0.000972	CcSEcCtD
Metoclopramide—Fatigue—Triamcinolone—psoriasis	6.94e-05	0.00097	CcSEcCtD
Metoclopramide—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.91e-05	0.000967	CcSEcCtD
Metoclopramide—Asthenia—Cyclosporine—psoriasis	6.9e-05	0.000965	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—NDUFA5—psoriasis	6.87e-05	0.00291	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.85e-05	0.0029	CbGpPWpGaD
Metoclopramide—Hypotension—Betamethasone—psoriasis	6.82e-05	0.000954	CcSEcCtD
Metoclopramide—Hypotension—Dexamethasone—psoriasis	6.82e-05	0.000954	CcSEcCtD
Metoclopramide—Urticaria—Hydrocortisone—psoriasis	6.79e-05	0.00095	CcSEcCtD
Metoclopramide—Body temperature increased—Hydrocortisone—psoriasis	6.76e-05	0.000945	CcSEcCtD
Metoclopramide—Convulsion—Prednisone—psoriasis	6.75e-05	0.000944	CcSEcCtD
Metoclopramide—Asthenia—Mycophenolate mofetil—psoriasis	6.73e-05	0.000941	CcSEcCtD
Metoclopramide—Hypertension—Prednisone—psoriasis	6.73e-05	0.000941	CcSEcCtD
Metoclopramide—Feeling abnormal—Triamcinolone—psoriasis	6.63e-05	0.000927	CcSEcCtD
Metoclopramide—Anxiety—Prednisone—psoriasis	6.61e-05	0.000925	CcSEcCtD
Metoclopramide—Insomnia—Betamethasone—psoriasis	6.6e-05	0.000924	CcSEcCtD
Metoclopramide—Insomnia—Dexamethasone—psoriasis	6.6e-05	0.000924	CcSEcCtD
Metoclopramide—Diarrhoea—Cyclosporine—psoriasis	6.58e-05	0.00092	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—JUN—psoriasis	6.47e-05	0.00274	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Prednisolone—psoriasis	6.45e-05	0.000902	CcSEcCtD
Metoclopramide—Diarrhoea—Mycophenolate mofetil—psoriasis	6.42e-05	0.000898	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.41e-05	0.00271	CbGpPWpGaD
Metoclopramide—Urticaria—Triamcinolone—psoriasis	6.39e-05	0.000894	CcSEcCtD
Metoclopramide—Body temperature increased—Triamcinolone—psoriasis	6.36e-05	0.00089	CcSEcCtD
Metoclopramide—Dizziness—Cyclosporine—psoriasis	6.36e-05	0.000889	CcSEcCtD
Metoclopramide—Oedema—Prednisone—psoriasis	6.36e-05	0.000889	CcSEcCtD
Metoclopramide—Hypersensitivity—Hydrocortisone—psoriasis	6.3e-05	0.000881	CcSEcCtD
Metoclopramide—Fatigue—Betamethasone—psoriasis	6.3e-05	0.00088	CcSEcCtD
Metoclopramide—Fatigue—Dexamethasone—psoriasis	6.3e-05	0.00088	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—CYP2S1—psoriasis	6.25e-05	0.00264	CbGpPWpGaD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.23e-05	0.00263	CbGpPWpGaD
Metoclopramide—Tachycardia—Prednisone—psoriasis	6.21e-05	0.000868	CcSEcCtD
Metoclopramide—Dizziness—Mycophenolate mofetil—psoriasis	6.2e-05	0.000868	CcSEcCtD
Metoclopramide—Asthenia—Hydrocortisone—psoriasis	6.13e-05	0.000858	CcSEcCtD
Metoclopramide—DRD3—GPCR downstream signaling—HCAR2—psoriasis	6.1e-05	0.00258	CbGpPWpGaD
Metoclopramide—Rash—Cyclosporine—psoriasis	6.06e-05	0.000848	CcSEcCtD
Metoclopramide—Dermatitis—Cyclosporine—psoriasis	6.06e-05	0.000847	CcSEcCtD
Metoclopramide—Headache—Cyclosporine—psoriasis	6.02e-05	0.000843	CcSEcCtD
Metoclopramide—Feeling abnormal—Dexamethasone—psoriasis	6.02e-05	0.000842	CcSEcCtD
Metoclopramide—Feeling abnormal—Betamethasone—psoriasis	6.02e-05	0.000842	CcSEcCtD
Metoclopramide—Hypersensitivity—Triamcinolone—psoriasis	5.93e-05	0.000829	CcSEcCtD
Metoclopramide—Rash—Mycophenolate mofetil—psoriasis	5.91e-05	0.000827	CcSEcCtD
Metoclopramide—Dermatitis—Mycophenolate mofetil—psoriasis	5.91e-05	0.000826	CcSEcCtD
Metoclopramide—Headache—Mycophenolate mofetil—psoriasis	5.88e-05	0.000822	CcSEcCtD
Metoclopramide—Diarrhoea—Hydrocortisone—psoriasis	5.85e-05	0.000818	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism—CYP2S1—psoriasis	5.84e-05	0.00247	CbGpPWpGaD
Metoclopramide—Leukopenia—Methotrexate—psoriasis	5.83e-05	0.000815	CcSEcCtD
Metoclopramide—Urticaria—Dexamethasone—psoriasis	5.8e-05	0.000811	CcSEcCtD
Metoclopramide—Urticaria—Betamethasone—psoriasis	5.8e-05	0.000811	CcSEcCtD
Metoclopramide—Dizziness—Prednisolone—psoriasis	5.79e-05	0.000809	CcSEcCtD
Metoclopramide—Asthenia—Triamcinolone—psoriasis	5.77e-05	0.000807	CcSEcCtD
Metoclopramide—Body temperature increased—Dexamethasone—psoriasis	5.77e-05	0.000807	CcSEcCtD
Metoclopramide—Body temperature increased—Betamethasone—psoriasis	5.77e-05	0.000807	CcSEcCtD
Metoclopramide—Insomnia—Prednisone—psoriasis	5.75e-05	0.000804	CcSEcCtD
Metoclopramide—Nausea—Cyclosporine—psoriasis	5.71e-05	0.000799	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—VEGFA—psoriasis	5.65e-05	0.00239	CbGpPWpGaD
Metoclopramide—Dizziness—Hydrocortisone—psoriasis	5.65e-05	0.00079	CcSEcCtD
Metoclopramide—Convulsion—Methotrexate—psoriasis	5.64e-05	0.000789	CcSEcCtD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.64e-05	0.00238	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CCL20—psoriasis	5.61e-05	0.00237	CbGpPWpGaD
Metoclopramide—Nausea—Mycophenolate mofetil—psoriasis	5.57e-05	0.000779	CcSEcCtD
Metoclopramide—DRD3—Signaling by GPCR—HCAR2—psoriasis	5.54e-05	0.00234	CbGpPWpGaD
Metoclopramide—Rash—Prednisolone—psoriasis	5.52e-05	0.000772	CcSEcCtD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.52e-05	0.00233	CbGpPWpGaD
Metoclopramide—Dermatitis—Prednisolone—psoriasis	5.51e-05	0.000771	CcSEcCtD
Metoclopramide—Fatigue—Prednisone—psoriasis	5.48e-05	0.000767	CcSEcCtD
Metoclopramide—Headache—Prednisolone—psoriasis	5.48e-05	0.000767	CcSEcCtD
Metoclopramide—HTR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.45e-05	0.0023	CbGpPWpGaD
Metoclopramide—Rash—Hydrocortisone—psoriasis	5.39e-05	0.000754	CcSEcCtD
Metoclopramide—Dermatitis—Hydrocortisone—psoriasis	5.38e-05	0.000753	CcSEcCtD
Metoclopramide—Confusional state—Methotrexate—psoriasis	5.36e-05	0.000749	CcSEcCtD
Metoclopramide—Headache—Hydrocortisone—psoriasis	5.35e-05	0.000749	CcSEcCtD
Metoclopramide—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	5.33e-05	0.00225	CbGpPWpGaD
Metoclopramide—Dizziness—Triamcinolone—psoriasis	5.32e-05	0.000744	CcSEcCtD
Metoclopramide—Feeling abnormal—Prednisone—psoriasis	5.24e-05	0.000733	CcSEcCtD
Metoclopramide—Asthenia—Dexamethasone—psoriasis	5.24e-05	0.000733	CcSEcCtD
Metoclopramide—Asthenia—Betamethasone—psoriasis	5.24e-05	0.000733	CcSEcCtD
Metoclopramide—Nausea—Prednisolone—psoriasis	5.2e-05	0.000727	CcSEcCtD
Metoclopramide—Nausea—Hydrocortisone—psoriasis	5.08e-05	0.00071	CcSEcCtD
Metoclopramide—Rash—Triamcinolone—psoriasis	5.07e-05	0.00071	CcSEcCtD
Metoclopramide—Dermatitis—Triamcinolone—psoriasis	5.07e-05	0.000709	CcSEcCtD
Metoclopramide—Urticaria—Prednisone—psoriasis	5.05e-05	0.000706	CcSEcCtD
Metoclopramide—Headache—Triamcinolone—psoriasis	5.04e-05	0.000705	CcSEcCtD
Metoclopramide—Body temperature increased—Prednisone—psoriasis	5.03e-05	0.000703	CcSEcCtD
Metoclopramide—Diarrhoea—Dexamethasone—psoriasis	5e-05	0.000699	CcSEcCtD
Metoclopramide—Diarrhoea—Betamethasone—psoriasis	5e-05	0.000699	CcSEcCtD
Metoclopramide—Hypotension—Methotrexate—psoriasis	4.97e-05	0.000695	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—TNF—psoriasis	4.84e-05	0.00205	CbGpPWpGaD
Metoclopramide—Dizziness—Betamethasone—psoriasis	4.83e-05	0.000675	CcSEcCtD
Metoclopramide—Dizziness—Dexamethasone—psoriasis	4.83e-05	0.000675	CcSEcCtD
Metoclopramide—Insomnia—Methotrexate—psoriasis	4.81e-05	0.000672	CcSEcCtD
Metoclopramide—Nausea—Triamcinolone—psoriasis	4.78e-05	0.000669	CcSEcCtD
Metoclopramide—Dyspnoea—Methotrexate—psoriasis	4.74e-05	0.000663	CcSEcCtD
Metoclopramide—Somnolence—Methotrexate—psoriasis	4.72e-05	0.000661	CcSEcCtD
Metoclopramide—Hypersensitivity—Prednisone—psoriasis	4.69e-05	0.000655	CcSEcCtD
Metoclopramide—DRD2—GPCR downstream signaling—HCAR2—psoriasis	4.67e-05	0.00197	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCL20—psoriasis	4.66e-05	0.00197	CbGpPWpGaD
Metoclopramide—Rash—Betamethasone—psoriasis	4.6e-05	0.000644	CcSEcCtD
Metoclopramide—Rash—Dexamethasone—psoriasis	4.6e-05	0.000644	CcSEcCtD
Metoclopramide—Dermatitis—Betamethasone—psoriasis	4.6e-05	0.000643	CcSEcCtD
Metoclopramide—Dermatitis—Dexamethasone—psoriasis	4.6e-05	0.000643	CcSEcCtD
Metoclopramide—Fatigue—Methotrexate—psoriasis	4.58e-05	0.000641	CcSEcCtD
Metoclopramide—Headache—Dexamethasone—psoriasis	4.57e-05	0.00064	CcSEcCtD
Metoclopramide—Headache—Betamethasone—psoriasis	4.57e-05	0.00064	CcSEcCtD
Metoclopramide—CHRM1—GPCR downstream signaling—HCAR2—psoriasis	4.57e-05	0.00193	CbGpPWpGaD
Metoclopramide—Asthenia—Prednisone—psoriasis	4.56e-05	0.000638	CcSEcCtD
Metoclopramide—Feeling abnormal—Methotrexate—psoriasis	4.38e-05	0.000612	CcSEcCtD
Metoclopramide—Diarrhoea—Prednisone—psoriasis	4.35e-05	0.000608	CcSEcCtD
Metoclopramide—Nausea—Dexamethasone—psoriasis	4.34e-05	0.000607	CcSEcCtD
Metoclopramide—Nausea—Betamethasone—psoriasis	4.34e-05	0.000607	CcSEcCtD
Metoclopramide—DRD2—GPCR ligand binding—CCL20—psoriasis	4.29e-05	0.00182	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—LEP—psoriasis	4.27e-05	0.0018	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HCAR2—psoriasis	4.24e-05	0.00179	CbGpPWpGaD
Metoclopramide—Urticaria—Methotrexate—psoriasis	4.22e-05	0.00059	CcSEcCtD
Metoclopramide—Dizziness—Prednisone—psoriasis	4.21e-05	0.000588	CcSEcCtD
Metoclopramide—Body temperature increased—Methotrexate—psoriasis	4.2e-05	0.000588	CcSEcCtD
Metoclopramide—CHRM1—GPCR ligand binding—CCL20—psoriasis	4.2e-05	0.00178	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HCAR2—psoriasis	4.15e-05	0.00176	CbGpPWpGaD
Metoclopramide—HTR4—GPCR ligand binding—CXCL8—psoriasis	4.15e-05	0.00175	CbGpPWpGaD
Metoclopramide—Rash—Prednisone—psoriasis	4.01e-05	0.000561	CcSEcCtD
Metoclopramide—Dermatitis—Prednisone—psoriasis	4.01e-05	0.00056	CcSEcCtD
Metoclopramide—Headache—Prednisone—psoriasis	3.98e-05	0.000557	CcSEcCtD
Metoclopramide—DRD3—Circadian rythm related genes—NOS2—psoriasis	3.98e-05	0.00168	CbGpPWpGaD
Metoclopramide—Hypersensitivity—Methotrexate—psoriasis	3.92e-05	0.000548	CcSEcCtD
Metoclopramide—HTR3A—SIDS Susceptibility Pathways—IL6—psoriasis	3.91e-05	0.00165	CbGpPWpGaD
Metoclopramide—Asthenia—Methotrexate—psoriasis	3.81e-05	0.000533	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.8e-05	0.00161	CbGpPWpGaD
Metoclopramide—Nausea—Prednisone—psoriasis	3.78e-05	0.000528	CcSEcCtD
Metoclopramide—DRD3—Circadian rythm related genes—PPARG—psoriasis	3.72e-05	0.00157	CbGpPWpGaD
Metoclopramide—Diarrhoea—Methotrexate—psoriasis	3.64e-05	0.000509	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism—CARM1—psoriasis	3.54e-05	0.0015	CbGpPWpGaD
Metoclopramide—Dizziness—Methotrexate—psoriasis	3.51e-05	0.000491	CcSEcCtD
Metoclopramide—Rash—Methotrexate—psoriasis	3.35e-05	0.000469	CcSEcCtD
Metoclopramide—Dermatitis—Methotrexate—psoriasis	3.35e-05	0.000468	CcSEcCtD
Metoclopramide—Headache—Methotrexate—psoriasis	3.33e-05	0.000466	CcSEcCtD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.31e-05	0.0014	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.27e-05	0.00138	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HCAR2—psoriasis	3.27e-05	0.00138	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—LEP—psoriasis	3.26e-05	0.00138	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—LEP—psoriasis	3.19e-05	0.00135	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CCL20—psoriasis	3.17e-05	0.00134	CbGpPWpGaD
Metoclopramide—Nausea—Methotrexate—psoriasis	3.16e-05	0.000441	CcSEcCtD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.06e-05	0.0013	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CARM1—psoriasis	3.05e-05	0.00129	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—NOS2—psoriasis	3.04e-05	0.00129	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—NOS2—psoriasis	2.98e-05	0.00126	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CCL20—psoriasis	2.88e-05	0.00122	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CARM1—psoriasis	2.85e-05	0.00121	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.85e-05	0.00121	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—PPARG—psoriasis	2.84e-05	0.0012	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TAGAP—psoriasis	2.84e-05	0.0012	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—PPARG—psoriasis	2.78e-05	0.00118	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.67e-05	0.00113	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—JUN—psoriasis	2.64e-05	0.00111	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SOCS1—psoriasis	2.56e-05	0.00108	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HCAR2—psoriasis	2.51e-05	0.00106	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—CXCL8—psoriasis	2.5e-05	0.00106	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HCAR2—psoriasis	2.45e-05	0.00104	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—TYK2—psoriasis	2.44e-05	0.00103	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CCL20—psoriasis	2.43e-05	0.00103	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CCL20—psoriasis	2.37e-05	0.001	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CXCL8—psoriasis	2.34e-05	0.000991	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.31e-05	0.000977	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CCL20—psoriasis	2.2e-05	0.000931	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CAT—psoriasis	2.18e-05	0.000921	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TAGAP—psoriasis	2.17e-05	0.000918	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CCL20—psoriasis	2.16e-05	0.000912	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CXCL8—psoriasis	2.13e-05	0.0009	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TAGAP—psoriasis	2.13e-05	0.000899	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—JUN—psoriasis	2.02e-05	0.000853	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.99e-05	0.000841	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—JUN—psoriasis	1.97e-05	0.000835	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—CXCL8—psoriasis	1.91e-05	0.00081	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—LEP—psoriasis	1.89e-05	0.0008	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—APOE—psoriasis	1.89e-05	0.0008	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CAT—psoriasis	1.88e-05	0.000794	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NDUFA5—psoriasis	1.86e-05	0.000786	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NFKBIA—psoriasis	1.76e-05	0.000746	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CAT—psoriasis	1.76e-05	0.000742	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TP53—psoriasis	1.74e-05	0.000736	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCL20—psoriasis	1.7e-05	0.000719	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—APOE—psoriasis	1.69e-05	0.000716	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—IL6—psoriasis	1.59e-05	0.000673	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP2S1—psoriasis	1.58e-05	0.000668	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.52e-05	0.000644	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CXCL8—psoriasis	1.51e-05	0.000641	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.49e-05	0.00063	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PPARG—psoriasis	1.47e-05	0.000623	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—APOE—psoriasis	1.46e-05	0.000617	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TYK2—psoriasis	1.44e-05	0.000611	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—APOE—psoriasis	1.36e-05	0.000577	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TP53—psoriasis	1.33e-05	0.000563	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—psoriasis	1.3e-05	0.000551	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCL20—psoriasis	1.3e-05	0.00055	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCL20—psoriasis	1.27e-05	0.000539	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PPARG—psoriasis	1.27e-05	0.000537	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CXCL8—psoriasis	1.26e-05	0.000532	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—IL6—psoriasis	1.22e-05	0.000515	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL6—psoriasis	1.2e-05	0.000506	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—IL6—psoriasis	1.19e-05	0.000504	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PPARG—psoriasis	1.19e-05	0.000502	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—JUN—psoriasis	1.17e-05	0.000494	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL8—psoriasis	1.16e-05	0.00049	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL8—psoriasis	1.13e-05	0.00048	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.13e-05	0.000478	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NFKB1—psoriasis	1.13e-05	0.000476	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—VEGFA—psoriasis	1.02e-05	0.000432	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—STAT3—psoriasis	1.01e-05	0.000428	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SOCS1—psoriasis	9.36e-06	0.000396	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—TYK2—psoriasis	8.93e-06	0.000378	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL8—psoriasis	8.56e-06	0.000362	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL8—psoriasis	7.77e-06	0.000329	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CARM1—psoriasis	7.72e-06	0.000326	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—psoriasis	7.72e-06	0.000326	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SOCS1—psoriasis	7.17e-06	0.000303	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL6—psoriasis	7.06e-06	0.000299	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SOCS1—psoriasis	7.01e-06	0.000297	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—LEP—psoriasis	6.91e-06	0.000292	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—APOE—psoriasis	6.91e-06	0.000292	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—TYK2—psoriasis	6.83e-06	0.000289	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—TYK2—psoriasis	6.69e-06	0.000283	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—psoriasis	6.55e-06	0.000277	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NFKBIA—psoriasis	6.44e-06	0.000272	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—psoriasis	6.41e-06	0.000271	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—psoriasis	5.95e-06	0.000252	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—psoriasis	5.82e-06	0.000246	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—LEP—psoriasis	5.29e-06	0.000224	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—APOE—psoriasis	5.29e-06	0.000224	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TYK2—psoriasis	5.27e-06	0.000223	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—LEP—psoriasis	5.17e-06	0.000219	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—APOE—psoriasis	5.17e-06	0.000219	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NFKBIA—psoriasis	4.93e-06	0.000208	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NFKBIA—psoriasis	4.82e-06	0.000204	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CAT—psoriasis	4.75e-06	0.000201	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—psoriasis	4.59e-06	0.000194	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL6—psoriasis	4.37e-06	0.000185	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JUN—psoriasis	4.27e-06	0.000181	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NFKB1—psoriasis	4.11e-06	0.000174	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TYK2—psoriasis	4.04e-06	0.000171	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TYK2—psoriasis	3.95e-06	0.000167	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—VEGFA—psoriasis	3.73e-06	0.000158	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—STAT3—psoriasis	3.69e-06	0.000156	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—APOE—psoriasis	3.69e-06	0.000156	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—psoriasis	3.51e-06	0.000149	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—psoriasis	3.44e-06	0.000145	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL6—psoriasis	3.34e-06	0.000141	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL6—psoriasis	3.27e-06	0.000138	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JUN—psoriasis	3.27e-06	0.000138	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARG—psoriasis	3.21e-06	0.000136	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JUN—psoriasis	3.2e-06	0.000135	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NFKB1—psoriasis	3.14e-06	0.000133	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NFKB1—psoriasis	3.08e-06	0.00013	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—VEGFA—psoriasis	2.85e-06	0.000121	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—STAT3—psoriasis	2.83e-06	0.000119	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—psoriasis	2.82e-06	0.000119	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—VEGFA—psoriasis	2.79e-06	0.000118	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—STAT3—psoriasis	2.77e-06	0.000117	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL6—psoriasis	2.58e-06	0.000109	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—psoriasis	2.16e-06	9.12e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—psoriasis	2.11e-06	8.92e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL6—psoriasis	1.97e-06	8.35e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL6—psoriasis	1.93e-06	8.17e-05	CbGpPWpGaD
